Casdin Capital, LLC
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 14, 2024), Casdin Capital, LLC reported 35 stock positions worth $1.5 billion. Its top holding was Biolife Solutions (BLFS) at 14.5% of the portfolio, followed by Revolution Medicines (RVMD, 12.4%) and Genedx (WGS, 9.9%). Compared with Q2 2024, it sold out of 3, added to 10 and reduced 6. The biggest buy was Illumina (ILMN, shares +56%) and the biggest sale an exit from Pliant Therapeutics (PLRX).
- Most Recent 13F
- Q2 2026
- Location
- New York, NY
- CIK
- 0001534261
- Portfolio Value
- $1.5B (Q3 2024)
- SEC Filing
- 0000919574-24-006736 ↗ filed Nov 14, 2024
Holdings Value
Holdings 35 stocks · $1.5B
| BLFS Biolife Solutions Inc. | 14.54% | 8,707,165 | $218.0M | No change |
| RVMD Revolution Medicines Inc. | 12.44% | 4,114,283 | $186.6M | Reduce -6.6% |
| WGS Genedx Holdings Corp. | 9.92% | 3,507,164 | $148.8M | Reduce -0.6% |
| LAB Standard Biotools Inc. | 9.17% | 71,254,677 | $137.5M | Add +11.4% |
| SRPT Sarepta Therapeutics Inc. | 8.94% | 1,073,500 | $134.1M | No change |
| ILMN Illumina Inc. | 6.52% | 750,000 | $97.8M | Add +56.3% |
| RNAM Avidity Biosciences Inc. | 6.38% | 2,084,841 | $95.8M | No change |
| RLAY Relay Therapeutics Inc. | 4.37% | 9,251,108 | $65.5M | Add +9.5% |
| ALNY Alnylam Pharmaceuticals Inc. | 3.12% | 170,000 | $46.8M | No change |
| EXAS Exact Sciences Corp. | 2.95% | 650,000 | $44.3M | No change |
| NTLA Intellia Therapeutics Inc. | 2.74% | 2,000,000 | $41.1M | No change |
| GPCR Structure Therapeutics Inc. | 2.05% | 700,000 | $30.7M | No change |
| BPMC Blueprint Medicines Corp. | 2.01% | 326,378 | $30.2M | No change |
| DNLI Denali Therapeutics Inc. | 1.92% | 990,000 | $28.8M | Reduce -23.9% |
| CDXS Codexis Inc. | 1.66% | 8,100,000 | $24.9M | Add +305.0% |
| VCYT Veracyte Inc. | 1.51% | 666,308 | $22.7M | Reduce -22.3% |
| NGNE Neurogene Inc. | 1.47% | 524,616 | $22.0M | No change |
| VERV Verve Therapeutics Inc. | 1.29% | 3,995,571 | $19.3M | Add +30.6% |
| BEAM Beam Therapeutics Inc. | 1.27% | 775,000 | $19.0M | Add +14.8% |
| TNYA Tenaya Therapeutics Inc. | 0.87% | 6,732,971 | $13.0M | No change |
| FDMT 4D Molecular Therapeutics Inc. | 0.83% | 1,150,000 | $12.4M | Add +43.8% |
| TSVT 2SEVENTY Bio Inc. | 0.63% | 2,000,000 | $9.4M | No change |
| TNGX Tango Therapeutics Inc. | 0.61% | 1,188,349 | $9.2M | No change |
| SNDX Syndax Pharmaceuticals Inc. | 0.61% | 475,000 | $9.1M | Add +216.7% |
| GH Guardant Health Inc. | 0.54% | 350,000 | $8.0M | Add +250.0% |
| CTNM Contineum Therapeutics Inc. Class A | 0.38% | 296,666 | $5.7M | No change |
| IPSC Century Therapeutics Inc. | 0.37% | 3,212,316 | $5.5M | Reduce -38.1% |
| GRAL Grail Inc. | 0.32% | 350,000 | $4.8M | Add +337.5% |
| ABSI Absci Corp. | 0.25% | 973,260 | $3.7M | No change |
| PACB Pacific Biosciences of Calif | 0.12% | 1,035,859 | $1.8M | No change |
| PRME Prime Medicine Inc. | 0.09% | 367,175 | $1.4M | No change |
| EXAI Exscientia Ltd. | 0.07% | 213,900 | $1.0M | No change |
| GLUE Monte Rosa Therapeutics Inc. | 0.03% | 86,014 | $456K | Reduce -67.0% |
| DNA Ginkgo Bioworks Holdings Inc. | 0.02% | 36,493 | $297K | No change |
| KRON Kronos Bio Inc. | 0.01% | 123,839 | $124K | No change |
Portfolio Sells Q2 2024 → Q3 2024
| PLRX Pliant Therapeutics Inc. | Sold out | 0.00% | −0.82 |
| IPSC Century Therapeutics Inc. | Reduce -38.1% | 0.37% | −0.64 |
| RVMD Revolution Medicines Inc. | Reduce -6.6% | 12.44% | −0.62 |
| DNLI Denali Therapeutics Inc. | Reduce -23.9% | 1.92% | −0.38 |
| KYTX Kyverna Therapeutics Inc. | Sold out | 0.00% | −0.33 |
| GLUE Monte Rosa Therapeutics Inc. | Reduce -67.0% | 0.03% | −0.04 |
| OMIC Singular Genomics Systems Inc. | Sold out | 0.00% | −0.03 |
| VCYT Veracyte Inc. | Reduce -22.3% | 1.51% | +0.09 |
| WGS Genedx Holdings Corp. | Reduce -0.6% | 9.92% | +2.88 |
Portfolio Buys Q2 2024 → Q3 2024
| ILMN Illumina Inc. | Add +56.3% | 6.52% | +2.70 |
| CDXS Codexis Inc. | Add +305.0% | 1.66% | +1.19 |
| LAB Standard Biotools Inc. | Add +11.4% | 9.17% | +0.52 |
| SNDX Syndax Pharmaceuticals Inc. | Add +216.7% | 0.61% | +0.37 |
| GH Guardant Health Inc. | Add +250.0% | 0.54% | +0.31 |
| GRAL Grail Inc. | Add +337.5% | 0.32% | +0.23 |
| RLAY Relay Therapeutics Inc. | Add +9.5% | 4.37% | +0.16 |
| VERV Verve Therapeutics Inc. | Add +30.6% | 1.29% | +0.15 |
| BEAM Beam Therapeutics Inc. | Add +14.8% | 1.27% | +0.06 |
| FDMT 4D Molecular Therapeutics Inc. | Add +43.8% | 0.83% | −0.45 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 43 | $2.0B | RVMD, RLAY, WGS, BLFS, ILMN |
| Q1 2026 | 40 | $1.3B | RVMD, WGS, RLAY, BLFS, LAB |
| Q4 2025 | 38 | $1.6B | WGS, RVMD, BLFS, LAB, RLAY |
| Q3 2025 | 32 | $1.2B | WGS, BLFS, RVMD, LAB, RNAM |
| Q2 2025 | 33 | $1.1B | WGS, BLFS, RVMD, LAB, ILMN |
| Q1 2025 | 44 | $1.2B | WGS, BLFS, RVMD, LAB, RNAM |
| Q4 2024 | 38 | $1.5B | WGS, BLFS, RVMD, SRPT, LAB |
| Q3 2024 | 35 | $1.5B | BLFS, RVMD, WGS, LAB, SRPT |
| Q2 2024Amended | 38 | $1.3B | BLFS, RVMD, SRPT, LAB, WGS |
| Q1 2024 | 36 | $1.3B | RVMD, LAB, BLFS, SRPT, RLAY |